Krsnaa Diagnostics Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹176Cr
- +8% YoY
- +0.6% QoQ
- Net profit
- ₹20Cr
- +11.1% YoY
- −4.8% QoQ
- Margin
- 29%
- +3 pp YoY
- −2 pp QoQ
The short version
Volume growth currently subdued (~4-5%) compared to industry (~10%) due to suspension of some projects like BMC, but expected to improve with initiatives and awareness campaigns. EBITDA grew by 19% YoY to INR 524 million with a 120 bps margin expansion to 27%.
From Krsnaa Diagnost.'s Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Volume growth currently subdued (~4-5%) compared to industry (~10%) due to suspension of some projects like BMC, but expected to improve with initiatives and awareness campaigns.
- Management expects volume and revenue growth to be higher than industry averages going forward.
- Rajasthan PPP contract rollout underway; full implementation of labs and collection centers expected over 6-9 months, with meaningful revenue from next financial year.
- Retail diagnostics (RPL) rapidly scaling, contributing ~6% of revenues; expected to grow to 5%-8% by FY '26.
- Retail business targeted to breakeven by FY '26 with 18%-20% revenue contribution anticipated within 1-1.5 years.
- Expansion in Maharashtra, Punjab, Assam, and Odisha, leveraging PPP backbone to accelerate retail growth.
2 more points from Krsnaa Diagnost.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Fundraising & Capital Structure
See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is actively pursuing tenders but it is too early to provide specific details about the current tender pipeline.
- As tenders come up, the company will share details accordingly.
- The Rajasthan PPP contract is a major new order with CAPEX estimated around INR 200-250 crores, expected to start generating revenues from FY 2027.
- The Rajasthan project includes 42 mother labs, 135 satellite labs, and over 1,300 collection centers targeted for full operations by FY 2026.
- There is ongoing implementation and expansion of radiology and pathology centers in Maharashtra, Madhya Pradesh, and Uttar Pradesh within the current order book.
2 more points from Krsnaa Diagnost.'s call on order book
Create a free account to keep reading this call
Krsnaa Diagnost. — Quarterly revenue & net profit
Krsnaa Diagnost. Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 176 | 163 | +8% | 175 | +0.6% |
| Operating profit (EBITDA) | 50 | 43 | +16.3% | 53 | -5.7% |
| Operating margin | 29% | 26% | +3 pp | 31% | -2 pp |
| Profit before tax | 26 | 24 | +8.3% | 29 | -10.3% |
| Net profit (PAT) | 20 | 18 | +11.1% | 21 | -4.8% |
| EPS (₹) | 6.03 | 5.63 | +7.1% | 6.53 | -7.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Krsnaa Diagnostics's management said in earlier quarters
Others in Healthcare Services this season
- Aster DM Quality (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
- Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
- Syngene International (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
- Yatharth Hospital & Trauma Care Services (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Krsnaa Diagnost. and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Krsnaa Diagnost. Q1 FY26 results?
Volume growth currently subdued (~4-5%) compared to industry (~10%) due to suspension of some projects like BMC, but expected to improve with initiatives and awareness campaigns. EBITDA grew by 19% YoY to INR 524 million with a 120 bps margin expansion to 27%.
What is Krsnaa Diagnost. share price analysis?
Krsnaa Diagnost. currently shows a neutral. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.
Is Krsnaa Diagnost. planning capital expenditure?
Rajasthan PPP project: CAPEX increased to around INR 200-250 crores, involving 42 mother labs, 135 satellite labs, and 1,335 collection centers; rollout phased over next 6-9 months, with revenues starting FY '27.
Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
